---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053308"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-08-05T20:04:48+00:00"
generated_at: "2026-08-05T20:06:27.958497+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vanda Q2 2026 net loss $62.5M ($1.04/share); Fanapt sales up 23% to $36M; reiterates FY revenue guidance $240-290M

## Summary
- Net loss $62.5M ($1.04 diluted EPS) in Q2 2026 vs net loss $27.2M ($0.46) in Q2 2025; operating loss $62.4M.
- Fanapt net product sales $36.0M (+23% YoY); total prescriptions up 31% YoY.
- Total net product sales $50.5M (-4% YoY); HETLIOZ sales $5.6M (-66% YoY) due to $7M shipment shift to Q3.
- Cash $170.0M as of June 30, 2026, down $32.3M in Q2; expects to fund operations through end of 2027.
- FY 2026 total revenue guidance reiterated at $240-290M; BYSANTI launch H2 2026; Quimilza PDUFA Dec 12, 2026.

## SEC filing metadata
- accession: 0001628280-26-053308
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-08-05T20:04:48+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/0001628280-26-053308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053308
- JSON: https://secwatch.observer/filing/0001628280-26-053308.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.